Evidence map›Paper›PMID 39609852›Full record

ArticleJournal of hematology & oncology2024

Evasion of immunosurveillance by the upregulation of Siglec15 in bladder cancer.

Dingshan Deng, Jiatong Xiao, Jinhui Liu, Huihuang Li, Minghui Hu, Bohan Zhou, Haisu Liang, Benyi Fan, Jinbo Chen, Xiaogen Kuang and 3 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology & oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dingshan DengDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Jiatong XiaoDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Jinhui LiuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Huihuang LiDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Minghui HuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Bohan ZhouDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Haisu LiangDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Benyi FanDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Jinbo ChenDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China. chenjinbo@csu.edu.cn.
Xiaogen KuangDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China. zndxkxg@csu.edu.cn.
Zhenyu NieDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China. 22023160@csu.edu.cn.
Jiao HuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China. hujiao@csu.edu.cn.
Xiongbing ZuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China. zuxbxy@csu.edu.cn.

Funding

Changsha Natural Science Foundation kq2208377China Postdoctoral Science Foundation 2023M733951China Postdoctoral Science Foundation 2024M753688Hunan Provincial Key Area Research Plan 2023SK2016National Natural Science Foundation of China 82303760National Postdoctoral Program for Innovative Talents BX20230431Natural Science Foundation of Hunan Province 2024JJ2093Postdoctoral Fellowship Program of CPSF GZC20233176Science and Technology Innovation Program of Hunan Province 2023RC3073Youth Science Foundation of Xiangya Hospital 2022Q20
6 · The paper itself

Abstract

Immunotherapy resistance in bladder cancer (BLCA) is associated with elevated levels of sialic acid-binding immunoglobulin-like lectin (Siglec15). This protein plays a crucial role in fostering a noninflammatory tumor microenvironment (TME), which is conducive to cancer progression. Our study confirmed that the overexpression of Siglec15 led to a reduction in CD8

Indexed as

Tumor MicroenvironmentUp-RegulationUrinary Bladder NeoplasmsAnimalsCD8-Positive T-LymphocytesCell Line, TumorHumansImmunoglobulinsImmunotherapyLectinsMembrane ProteinsMiceTumor EscapeImmunoglobulinsLectinsMembrane ProteinsSIGLEC15 protein, humanBladder cancerImmunotherapyNoninflamed tumor microenvironmentSiglec15

Identifiers

PMID39609852
PMCPMC11606300

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.